Top 3 Health Care Stocks You'll Regret Missing This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here's the latest list of major oversold players in this sector, having an RSI near or below 30.

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.

Share Price: $0.80

Min. Investment: $1,000

Valuation: $3.5B

Radiopharm Theranostics ADR RADX

On Jan. 10, Radiopharm Theranostics announced it will execute a private placement and will raise $5 million in proceeds. The company' stock fell around 11% over the past five days and has a 52-week low of $3.71.
RSI Value: 27.4
RADX Price Action: Shares of RADX closed at $4.40 on Wednesday.
Benzinga Pro's real-time newsfeed alerted to latest RADX news.

Surmodics Inc SRDX

On Feb. 3, Surmodics reported successful early clinical use of Pounce XL Thrombectomy System for non-surgical clot removal in iliac and femoral arteries. The company's stock fell around 15% over the past month and has a 52-week low of $25.21.
RSI Value: 29.9
SRDX Price Action: Shares of Surmodics gained 0.7% to close at $33.85 on Wednesday.
Benzinga Pro’s charting tool helped identify the trend in SRDX stock.

Merck & Co Inc MRK

On Feb. 4, Merck & Co reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for business development transactions and operational strength primarily drove the increase. The company's stock fell around 10% over the past five days and has a 52-week low of $87.33.
RSI Value: 28.4
MRK Price Action: Shares of Merck fell 1.2% to close at $89.67 on Wednesday.
Benzinga Pro’s signals feature notified of a potential breakout in MRK shares.